Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease

Journal of Clinical Oncology

Volumn 22, Issue 18, 2004, Pages 3726-3732

  D'Amico, Anthony V ^a   Renshaw, Andrew A ^a   Cote, Kerri ^a   Hurwitz, Mark ^a   Beard, Clair ^a   Loffredo, Marian ^a   Chen, Ming Hui ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADIATION DOSE; TREATMENT OUTCOME; ADULT; AGED; BIOPSY; CANCER STAGING; COHORT ANALYSIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; PROSTATE TUMOR; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY; COHORT STUDIES; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RISK FACTORS;

EID: 4644225078     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.01.164     Document Type: Article

References (19)

1. D'Amico AV, Moul J, Carroll P, et al: Surrogate marker for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Natl Cancer Inst 95:1376-1383, 2003
2. D'Amico AV, Moul J, Carroll P, et al: Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 21:2163-2172, 2003
3. D'Amico AV, Whittington R, Malkowicz SB, et al: The clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 18:1164-1172, 2000
4. D'Amico AV, Schultz D, Silver B, et al: The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external beam radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 49:679-684, 2001
5. Bolla M, Collette L, Blank L, et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360: 103-106, 2002
6. Gleason DF: Histologic grading and staging of prostatic carcinoma, in Tannenbaum M (ed): Urologic Pathology. Philadelphia, PA, Lea & Febiger, 1977, pp 171-187
7. Lee CT, Oesterling JE: Using prostate-specific antigen to eliminate the staging radionuclide bone scan. Urol Clin North Am 24:389-394, 1997
8. Greene FL, Page DL, Fleming ID, et al: American Joint Committee on Cancer: Manual for Staging Cancer (ed 6). New York, NY, Springer-Verlag, 2002. pp 337-346
9. Cox JD: Consensus statement: Guidelines for PSA following radiation therapy-American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37:1035-1041, 1997
10. Klein JP, Moeschberger ML (eds): Survival Analysis. New Vork, NY, Springer-Verlag, 1997, pp 229-263
11. Bahnson RR, Hanks GE, Huben RP, et al: NCCN practice guidelines for prostate cancer. Oncology (Huntingt) 14:111-119, 2000
12. Gaynor JJ, Feur EJ, Tan CC, et al: On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data. J Am Stat Assoc 88:400-409, 1993
13. Crawford ED: Epidemiology of prostate cancer. Urology 62:3-12, 2003 (suppl 1)
14. Stamey TA, McNeal JE, Yemoto CM, et al: Biological determinants of cancer progression in men with prostate cancer. JAMA 281:1395-1400, 1999
15. Freedland SJ, Aronson WJ, Terris MK, et al: Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate-specific antigen recurrence following radical prostatectomy: Results from SEARCH database. J Urol 169:2136-2141, 2003
16. Grossfeld GD, Chang JJ, Broering JM, et al: Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. J Urol 165:851-856, 2001
17. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1596, 1999
18. Bismar TA, Lewis JS Jr, Vollmer RT, et al: Multiple measures of carcinoma extent versus perineural invasion in prostate needle biopsy tissue in prediction of pathologic stage in a screening population. Am J Surg Pathol 27:432-440, 2003
19. Naya Y, Slaton JW, Troncoso P, et al: Tumor length and location of cancer on biopsy predict for side specific extraprostatic extension. J Urol 171:1093-1097, 2004